MCID: OPT009
MIFTS: 53

Optic Neuritis

Categories: Rare diseases, Eye diseases, Neuronal diseases

Aliases & Classifications for Optic Neuritis

MalaCards integrated aliases for Optic Neuritis:

Name: Optic Neuritis 12 76 53 37 55 6 44 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:1210
ICD10 33 H46 H46.9
ICD9CM 35 377.3 377.30
MeSH 44 D009902
NCIt 50 C84950
KEGG 37 H01717
UMLS 73 C0029134

Summaries for Optic Neuritis

NIH Rare Diseases : 53 Optic neuritis is inflammation of the optic nerve, the nerve that carries the visual signal from the eye to the brain. The condition may cause sudden, reduced vision in the affected eye(s). While the cause of optic neuritis is unknown, it has been associated with autoimmune diseases, infections, multiple sclerosis, drug toxicity and deficiency of vitamin B-12. Vision often returns to normal within 2-3 weeks without treatment. In some cases, corticosteroids are given to speed recovery. If known, the underlying cause should be treated.

MalaCards based summary : Optic Neuritis is related to neuromyelitis optica and optic nerve disease, and has symptoms including eye manifestations An important gene associated with Optic Neuritis is AQP4 (Aquaporin 4), and among its related pathways/superpathways are Th1 Differentiation Pathway and Toxoplasmosis. The drugs Methylprednisolone and Prednisolone have been mentioned in the context of this disorder. Affiliated tissues include optic nerve which may cause a complete or partial loss of vision, eye and brain, and related phenotypes are behavior/neurological and hematopoietic system

Disease Ontology : 12 An optic nerve disease that results in inflammation located in optic nerve which may cause a complete or partial loss of vision.

Wikipedia : 76 Optic neuritis is a demyelinating inflammation of the optic nerve. It is also known as optic papillitis... more...

Related Diseases for Optic Neuritis

Diseases related to Optic Neuritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 249)
# Related Disease Score Top Affiliating Genes
1 neuromyelitis optica 32.8 AQP4 HLA-DRB1 MBP MOG
2 optic nerve disease 32.2 AQP4 MBP MOG MT-ND4
3 transverse myelitis 30.9 AQP4 MBP TNF
4 panencephalitis, subacute sclerosing 30.9 MBP MOG
5 myelitis 30.7 AQP4 MBP MOG TNF
6 encephalitis 30.7 AQP4 CCR5 MOG
7 acute disseminated encephalomyelitis 30.6 AQP4 HLA-DRB1 MBP MOG
8 allergic encephalomyelitis 30.5 MBP MOG PLP1
9 pediatric multiple sclerosis 30.5 HLA-DRB1 MOG
10 rubella 30.4 HLA-DRB1 MOG TNF
11 panuveitis 30.3 HLA-DRB1 TNF
12 cytomegalovirus retinitis 30.3 CCR5 TNF
13 miller fisher syndrome 30.3 MAG TNF
14 neuroretinitis 30.2 AQP4 MOG
15 relapsing-remitting multiple sclerosis 30.2 AQP4 MBP MOG TNF
16 psoriatic arthritis 29.4 HLA-DRB1 LTA TNF
17 polyneuropathy 29.0 MAG MBP MPZ
18 polyradiculoneuropathy 28.9 MAG MBP MPZ
19 neuritis 28.8 AQP4 MAG MBP MOG MPZ MT-ND4
20 demyelinating disease 28.7 AQP4 MAG MBP MOG PLP1 TNF
21 charcot-marie-tooth disease 27.4 CNTF MAG MBP MPZ PLP1
22 multiple sclerosis 25.1 AQP4 CCR5 CNTF HLA-DRB1 LTA MAG
23 isolated optic neuritis 12.2
24 chronic relapsing inflammatory optic neuropathy 11.7
25 optic papillitis 11.3
26 microscopic polyangiitis 10.7 HLA-DRB1 TNF
27 beryllium disease 10.7 HLA-DRB1 TNF
28 autoimmune pancreatitis 10.7 HLA-DRB1 TNF
29 chronic beryllium disease 10.7 HLA-DRB1 TNF
30 anca-associated vasculitis 10.7 HLA-DRB1 TNF
31 lichen sclerosus 10.7 HLA-DRB1 TNF
32 acute hemorrhagic leukoencephalitis 10.6 AQP4 MBP
33 actinic prurigo 10.6 HLA-DRB1 TNF
34 nontuberculous mycobacterial lung disease 10.6 HLA-DRB1 TNF
35 microscopic colitis 10.6 HLA-DRB1 TNF
36 central nervous system vasculitis 10.6 HLA-DRB1 TNF
37 retinitis 10.6
38 rheumatoid vasculitis 10.6 HLA-DRB1 TNF
39 alveolar echinococcosis 10.5 HLA-DRB1 TNF
40 traumatic brain injury 10.5 AQP4 MBP
41 balo concentric sclerosis 10.5 AQP4 MBP MOG
42 internuclear ophthalmoplegia 10.5 AQP4 MBP MOG
43 mucocutaneous leishmaniasis 10.5 CCR5 TNF
44 hemorrhagic fever 10.5 HLA-DRB1 TNF
45 congenital hydrocephalus 10.4 MBP TNF
46 orofacial granulomatosis 10.4 CCR5 TNF
47 cranial nerve disease 10.3 AQP4 MOG MT-ND4
48 neuropathy 10.3
49 mannosidosis, beta a, lysosomal 10.3 MAG MBP
50 spondylarthropathy 10.3 LTA TNF

Comorbidity relations with Optic Neuritis via Phenotypic Disease Network (PDN):


Hypertension, Essential Temporal Arteritis

Graphical network of the top 20 diseases related to Optic Neuritis:



Diseases related to Optic Neuritis

Symptoms & Phenotypes for Optic Neuritis

UMLS symptoms related to Optic Neuritis:


eye manifestations

MGI Mouse Phenotypes related to Optic Neuritis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.07 MBP AQP4 MOG CCR5 MPZ CNTF
2 hematopoietic system MP:0005397 10.02 MBP AQP4 MOG CCR5 MPZ CNTF
3 homeostasis/metabolism MP:0005376 9.96 MBP AQP4 CCR5 MPZ CNTF PLP1
4 immune system MP:0005387 9.9 MBP AQP4 MOG CCR5 MPZ CNTF
5 nervous system MP:0003631 9.65 MBP AQP4 MOG CCR5 MPZ CNTF
6 vision/eye MP:0005391 9.17 MBP AQP4 MOG CCR5 PLP1 LTA

Drugs & Therapeutics for Optic Neuritis

Drugs for Optic Neuritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 169)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
2
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
3
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 53-03-2 5865
4
Glatiramer Acetate Approved, Investigational Phase 4,Phase 3,Phase 2 147245-92-9 3081884
5
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
6
Mycophenolic acid Approved Phase 4 24280-93-1 446541
7
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
8
Interferon beta-1a Approved, Investigational Phase 4,Phase 3 145258-61-3 6438354
9
Interferon beta-1b Approved Phase 4,Phase 2,Phase 3 145155-23-3
10
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
11
Azithromycin Approved Phase 4 83905-01-5 55185 447043
12
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
13
Clarithromycin Approved Phase 4 81103-11-9 84029
14
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
15
Linezolid Approved, Investigational Phase 4 165800-03-3 441401
16
Ofloxacin Approved Phase 4 82419-36-1 4583
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1 59-30-3 6037
18
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
19 Adrenocorticotropic Hormone Phase 4,Early Phase 1
20 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 beta-endorphin Phase 4,Early Phase 1
25 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Melanocyte-Stimulating Hormones Phase 4,Early Phase 1
31 Methylprednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Methylprednisolone Hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Neuroprotective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Prednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Prednisolone hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Prednisolone phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Not Applicable
40 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
41 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Anti-Bacterial Agents Phase 4,Phase 2
43 Antibiotics, Antitubercular Phase 4
44 Anti-Infective Agents Phase 4,Phase 2,Phase 3
45 Antitubercular Agents Phase 4
46 Analgesics Phase 4,Phase 2
47 Topoisomerase Inhibitors Phase 4
48 Antimetabolites Phase 4,Phase 3,Phase 2,Not Applicable
49 Vitamin B Complex Phase 4,Phase 1
50 Antiviral Agents Phase 4,Phase 2,Phase 3

Interventional clinical trials:

(show top 50) (show all 108)
# Name Status NCT ID Phase Drugs
1 A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis Unknown status NCT01838174 Phase 4 ACTHAR Gel (ACTH);IV steroids with oral taper
2 Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) Unknown status NCT00910598 Phase 4 glatiramer acetate
3 Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Unknown status NCT02809079 Phase 4 Mycophenolate mofetil;Prednisone
4 Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Unknown status NCT02021825 Phase 4 Mitoxantrone
5 Effect of High-Dose Prednisolone (Solu Dacortin®) Treatment on Choroidal and Optic Nerve Head Blood Flow in Humans Completed NCT00312325 Phase 4 Prednisolone
6 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Completed NCT00179478 Phase 4 interferon beta 1a 30 ug IM once weekly
7 Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse Completed NCT00753792 Phase 4 methylprednisolone;methylprednisolone;Placebo
8 A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults Completed NCT01427309 Phase 4
9 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
10 Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis Completed NCT01795872 Phase 4
11 Linezolid for Treatment of Nontuberculous Mycobacterial Diseases Not yet recruiting NCT03220074 Phase 4 Oral Tablet
12 Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis Terminated NCT00854750 Phase 4 ACTHAR;ACTHAR;ACTHAR;ACTHAR
13 A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a Withdrawn NCT00771043 Phase 4 TYSABRI and AVONEX
14 Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event. Withdrawn NCT00037115 Phase 4 interferon beta 1a;methotrexate;methylprednisolone
15 Simvastatin Treatment of Patients With Acute Optic Neuritis Unknown status NCT00261326 Phase 3 simvastatin;placebo
16 Optic Neuritis Treatment Trial (ONTT) Unknown status NCT00000146 Phase 3 Methylprednisolone;Prednisone
17 Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone Unknown status NCT00004645 Phase 3
18 Ampyra for Optic Neuritis in MS Completed NCT01337986 Phase 2, Phase 3 Dalfampridine/Placebo;Placebo/Dalfampridine
19 A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon) Completed NCT00856635 Phase 3 Glatiramer Acetate;placebo
20 Optic Neuritis Recovery After Oral or IV Corticosteroids Completed NCT01524250 Phase 2, Phase 3 corticosteroids;corticosteroids
21 Intravenous Immunoglobulin Therapy in Optic Neuritis Completed NCT00000117 Phase 3 Immunoglobulin
22 Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049) Completed NCT01345240 Phase 3
23 Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients Completed NCT03002038 Phase 2, Phase 3 Azathioprine;Rituximab
24 Erythropoietin in Methanol Associated Optic Neuropathy: A Phase-2 Clinical Trial (EPO-MAON Study) Recruiting NCT02376881 Phase 3 Erythropoietin
25 Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders Recruiting NCT03350633 Phase 2, Phase 3 Tocilizumab Injection;Azathioprine
26 A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders Recruiting NCT03330418 Phase 3
27 Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSD Recruiting NCT02028884 Phase 3 satralizumab (SA237);Placebo
28 A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders Recruiting NCT02200770 Phase 2, Phase 3
29 Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial Active, not recruiting NCT01962571 Phase 3 Erythropoietin alfa;Placebo
30 Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis Active, not recruiting NCT02220244 Phase 3 MD1003 100mg capsule
31 A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study) Active, not recruiting NCT01892345 Phase 3 Eculizumab
32 Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD Active, not recruiting NCT02073279 Phase 3 satralizumab (SA237);Placebo
33 An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients Enrolling by invitation NCT02003144 Phase 3
34 MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study) Terminated NCT01647880 Phase 2, Phase 3 Verum arm receiving Gilenya®;Active Comparator receiving Extavia®
35 Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older Terminated NCT00976027 Phase 3
36 A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis Terminated NCT02398994 Phase 3 Intravenous Methylprednisolone;Intravenous Immunoglobulin
37 Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis Withdrawn NCT01337427 Phase 3 BIIB017
38 Effect of Vitamin D on Retinal Changes in Patient With Optic Neuritis by Optic Coherence Tomography Unknown status NCT01465893 Phase 2 Vitamin D;Vitamin D withheld
39 Amiloride Hydrochlorothiazide as Treatment of Acute Inflammation of the Optic Nerve Unknown status NCT01879527 Phase 2 Amiloride hydrochlorothiazide;Sugar pill
40 Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica Unknown status NCT01364246 Phase 1, Phase 2
41 AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis Unknown status NCT01228396 Phase 2 Hyperimmune caprine serum against HIV lysate
42 Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders Unknown status NCT02249676 Phase 2
43 BIIB033 In Acute Optic Neuritis (AON) Completed NCT01721161 Phase 2 Placebo
44 Amiloride Clinical Trial In Optic Neuritis Completed NCT01802489 Phase 2 Amiloride;Placebo
45 Safety and Efficacy Study of Erythropoietin as add-on Therapy of Methylprednisolone to Treat Acute Optic Neuritis Completed NCT00355095 Phase 2 Erythropoietin
46 Neuroprotection With Phenytoin in Optic Neuritis Completed NCT01451593 Phase 2 Phenytoin;Placebo
47 Visual Reconstitution Therapy After Optic Neuritis Completed NCT01274702 Phase 2
48 Long-Term Assessment of Remyelinating Therapy Completed NCT02657915 Phase 2 Placebo;BIIB033 100mg/Kg
49 Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) Completed NCT00395200 Phase 1, Phase 2
50 Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) Completed NCT02166346 Phase 2 Dalfampridine;Placebo

Search NIH Clinical Center for Optic Neuritis

Cochrane evidence based reviews: optic neuritis

Genetic Tests for Optic Neuritis

Anatomical Context for Optic Neuritis

The Foundational Model of Anatomy Ontology organs/tissues related to Optic Neuritis:

19
Optic Nerve Which May Cause A Complete Or Partial Loss Of Vision

MalaCards organs/tissues related to Optic Neuritis:

41
Eye, Brain, T Cells, Testes, Bone, Pituitary, Spinal Cord

Publications for Optic Neuritis

Articles related to Optic Neuritis:

(show top 50) (show all 825)
# Title Authors Year
1
Valuable Insights Into Visual Neuroplasticity After Optic Neuritis. ( 29297048 )
2018
2
Early Nodal and Paranodal Disruption in Autoimmune Optic Neuritis. ( 29444299 )
2018
3
Why Therapeutic Compliance in Optic Neuritis Deserves to Be More Than Just a Footnote: Response. ( 29923869 )
2018
4
Anatomical Wiring and Functional Networking Changes in the Visual System Following Optic Neuritis. ( 29297053 )
2018
5
Paediatric ADEM followed by optic neuritis: disease course, treatment response and outcome. ( 29443442 )
2018
6
Progressive inner nuclear layer dysfunction in non-optic neuritis eyes in MS. ( 29259999 )
2018
7
Association of Optic Neuritis with <i>CYP4F2</i> Gene Single Nucleotide Polymorphism and IL-17A Concentration. ( 29736281 )
2018
8
Structural and visual functional deficits in a rat model of neuromyelitis optica spectrum disorders related optic neuritis. ( 29913164 )
2018
9
Guillain-BarrAc syndrome and optic neuritis after Mycoplasma pneumoniae infection. ( 29429558 )
2018
10
Clinical features of demyelinating optic neuritis with seropositive myelin oligodendrocyte glycoprotein antibody in Chinese patients. ( 29363529 )
2018
11
Short-term effect of additional apheresis on visual acuity changes in patients with steroid-resistant optic neuritis in neuromyelitis optica spectrum disorders. ( 29802557 )
2018
12
MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study. ( 29808469 )
2018
13
Clinical presentation of optic neuritis with autoantibodies anti-myelin oligodendrocyte glycoprotein. ( 29972029 )
2018
14
High resolution retinal scanning reveals regional structural differences between MS and NMOSD optic neuritis regardless of antibody status. ( 29249380 )
2018
15
Early Diagnosis of Recurrent Optic Neuritis Using Contrast-Enhanced T2 Fluid-attenuated Inversion Recovery Imaging: a Case Report. ( 29976284 )
2018
16
Neuromyelitis Optica: Review and Utility of Testing Aquaporin-4 Antibody in Typical Optic Neuritis. ( 29766684 )
2018
17
Why Therapeutic Compliance in Optic Neuritis Deserves to be More Than Just a Footnote. ( 29901490 )
2018
18
Recurrent idiopathic neuroretinitis as a spectrum of atypical optic neuritis: a case report and literature review. ( 29538599 )
2018
19
Possible Combined Central and Peripheral Demyelination Presenting as Optic Neuritis, Cervical Myelitis, and Demyelinating Polyneuropathy with Marked Nerve Hypertrophy. ( 29540658 )
2018
20
Typical optic neuritis? ( 29941727 )
2018
21
Relapsing acute disseminated encephalomyelitis followed by optic neuritis in children; a clinical entity associated with anti-MOG antibody. ( 29790244 )
2018
22
Differentiating Neuromyelitis Optica-Related and Multiple Sclerosis-Related Acute Optic Neuritis Using Conventional Magnetic Resonance Imaging Combined With Readout-Segmented Echo-Planar Diffusion-Weighted Imaging. ( 29787495 )
2018
23
Erratum: Progressive inner nuclear layer dysfunction in non-optic neuritis eyes in MS. ( 29417957 )
2018
24
MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder. ( 29670575 )
2018
25
Retinal nerve fiber layer and ganglion cell layer changes on optical coherence tomography in early multiple sclerosis and optic neuritis cases. ( 29283135 )
2018
26
Advanced diffusion-weighted imaging in patients with optic neuritis deficit - value of reduced field of view DWI and readout-segmented DWI. ( 29417865 )
2018
27
Recurrent Optic Neuritis as the Initial Symptom in Demyelinating Diseases. ( 29856159 )
2018
28
Rituximab was effective for acute disseminated encephalomyelitis followed by recurrent optic neuritis with anti-myelin oligodendrocyte glycoprotein antibodies. ( 29661590 )
2018
29
Baseline Brain Activity Changes in Patients With Single and Relapsing Optic Neuritis. ( 29731712 )
2018
30
Time to steroid treatment in severe acute optic neuritis. ( 29931830 )
2018
31
Macular choroidal thickness and peripapillary retinal nerve fiber layer thickness in normal adults and patients with optic atrophy due to acute idiopathic demyelinating optic neuritis. ( 29856811 )
2018
32
Incidence and Causes of Overdiagnosis of Optic Neuritis. ( 29222573 )
2018
33
Diagnosis and treatment of anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis. ( 29445944 )
2018
34
Clinical Characteristics of Pediatric Optic Neuritis With Myelin Oligodendrocyte Glycoprotein Seropositive: A Cohort Study. ( 29778487 )
2018
35
A Pediatric Case of Relapsing-Remitting Multiple Sclerosis Onset following Varicella Zoster Ophthalmicus with Optic Neuritis. ( 29785316 )
2018
36
Unusual case of cerebral demyelination and bilateral optic neuritis in an infant with suppurative BCG lymphadenitis. ( 29848532 )
2018
37
Myelin oligodendrocyte glycoprotein-positive optic neuritis masquerading as pseudotumor cerebri at presentation. ( 29938337 )
2018
38
Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France. ( 28914353 )
2017
39
Paediatric optic neuritis: factors leading to unfavourable outcome and relapses. ( 28903961 )
2017
40
Postinfectious Anti-Myelin Oligodendrocyte Glycoprotein Antibody Positive Optic Neuritis and Myelitis. ( 28820014 )
2017
41
No evidence of association between optic neuritis and secondary LHON mtDNA mutations in patients with multiple sclerosis. ( 28802665 )
2017
42
A case of MOG antibody-positive bilateral optic neuritis and meningoganglionitis following a genital herpes simplex virus infection. ( 29055448 )
2017
43
Long-term structural retinal changes in patients with optic neuritis related to multiple sclerosis. ( 28860702 )
2017
44
Bevacizumab for Radiation Induced Optic Neuritis Among Aggressive Residual/Recurrent Suprasellar Tumors: More Than a Mere Antineoplastic Effect. ( 28754639 )
2017
45
Trans-synaptic degeneration in the optic pathway. A study in clinically isolated syndrome and early relapsing-remitting multiple sclerosis with or without optic neuritis. ( 28850630 )
2017
46
Optic neuritis in a patient with celiac disease. ( 28803640 )
2017
47
Optical Coherence Tomography and Subclinical Optical Neuritis in Longitudinally Extensive Transverse Myelitis. ( 29184337 )
2017
48
Optic neuritis in dogs: 96 cases (1983-2016). ( 29251394 )
2017
49
Time is vision in recurrent optic neuritis. ( 28823952 )
2017
50
Transorbital Sonography and Visual Outcome for the Diagnosis and Monitoring of Optic Neuritis. ( 27862614 )
2017

Variations for Optic Neuritis

ClinVar genetic disease variations for Optic Neuritis:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MT-ND4 NC_012920.1: m.11443A> C single nucleotide variant Uncertain significance GRCh37 Chromosome MT, 11443: 11443
2 MT-ND4 NC_012920.1: m.11443A> C single nucleotide variant Uncertain significance GRCh38 Chromosome MT, 11443: 11443

Expression for Optic Neuritis

Search GEO for disease gene expression data for Optic Neuritis.

Pathways for Optic Neuritis

GO Terms for Optic Neuritis

Cellular components related to Optic Neuritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.96 AQP4 CCR5 HLA-DRB1 LTA MAG MBP
2 myelin sheath GO:0043209 9.26 MAG MBP MPZ PLP1
3 compact myelin GO:0043218 9.16 MAG MBP
4 external side of plasma membrane GO:0009897 9.02 AQP4 CCR5 HLA-DRB1 MOG TNF
5 membrane GO:0016020 10.06 AQP4 CCR5 HLA-DRB1 LTA MAG MBP

Biological processes related to Optic Neuritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.65 CCR5 HLA-DRB1 LTA MBP TNF
2 response to hypoxia GO:0001666 9.63 LTA MT-ND4 SOD3
3 negative regulation of growth of symbiont in host GO:0044130 9.43 LTA TNF
4 cell-cell adhesion via plasma-membrane adhesion molecules GO:0098742 9.4 MAG MPZ
5 central nervous system myelination GO:0022010 9.37 MAG PLP1
6 myelination GO:0042552 9.33 MBP MPZ PLP1
7 axon ensheathment GO:0008366 9.32 MBP PLP1
8 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 8.96 LTA TNF
9 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 8.62 LTA TNF

Molecular functions related to Optic Neuritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor receptor binding GO:0005164 9.16 LTA TNF
2 structural constituent of myelin sheath GO:0019911 8.96 MBP PLP1
3 virus receptor activity GO:0001618 8.8 CCR5 HLA-DRB1 MOG

Sources for Optic Neuritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....